Research Paper Volume 13, Issue 21 pp 24155—24170
Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma
Figure 5. The roles of the immune signature in evaluating ICI treatment efficacy for melanoma. (A) Overall survival (OS) rate and (B) progression-free survival (PFS) rate differences of low- and high-risk groups were illustrated by Kaplan-Meier survival curves. Multivariate Cox regression models were conducted with sex, stage, and treatment type taken into account to elucidate the connections of the immune signature with (C) OS and (D) PFS outcomes. (E) The proportion of melanoma ICI responders in patients with low-risk versus high-risk signature scores was illustrated.